SBIR/STTR Research Award
IMPROVED CLASSIFIERS FOR AUTOMATED MULTIPLEX FISH
Award amount
$99,993Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Advanced Digital Imaging Research, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Abstract, from the application): Automated karyotyping is an
important procedure in cytogenetics labs worldwide. Multiplex fluorescence in
situ hybridization (M-FISH) is a recent development that uses multicolor
chromosome painting probes and multispectral image analysis to identify subtle
and complex chromosomal rearrangements. It promises to make automated
karyotyping faster, more accurate, and easier to interpret both in clinical
situation and in cancer research. The major factor limiting the ability of
M-FISH to resolve the chromosomal origin of the DNA in abnormal chromosomes is
pixel classification accuracy. The goal of this project to develop improved
software techniques for M-FISH to improve significantly the accuracy of pixel
classification in M-FISH systems, but maximizing the impact of this important
new technology on the practice of cytogenetics. The instruments that are
commercially available now implement only rudimentary pixel classification
algorithms for identifying the homologue origin of DNA. In this project, we
will apply state-of-the-art pattern recognition techniques to M-FISH to improve
pixel classification accuracy far beyond what is current offered by commercial
systems. The improved M-FISH system that will result will automatically find
and flag both subtle and complex structural abnormalities (insertions and
translocations of genetic material) assisting both cancer research and genetic
diagnosis. Once we have established feasibility in Phase I, we will use Phase
II to develop the improvements fully and test the system in routine clinical
use on prenatal, postnatal and cancer specimens from amniocentesis, peripheral
blood, and bone marrow. The enhancements will be integrated into PSI's M- FISH
instrument, currently part of the PowerGene line of cytogenetics automation
products. The resulting commercial instrument will be superior to currently
available systems for elucidating structural rearrangements within chromosomes.
PROPOSED COMMERCIAL APPLICATION:
As soon as the new techniques are developed and qualified for routine application, they
will be incorporated into PSI's PowerGene product line of cytogenetics automation equipment,
both in new systems sold and as an upgrade to existing systems already in use in
cytogenetics labs. Newly developed chromosome painting probes will be added to PSI's
reagent product line, thus commercializing the technology quickly.
Technology keywords
Not reported